Browse Studies — Arctuva

Phase 3

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ova…

Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal Neoplasms+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213804

Ovarian Cancer Detection by Uterine Lavage DNA and Serum Proteins: a Phase 2 Biomarker Study

The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and…

Ovarian NeoplasmsOvarian Epithelial CarcinomaFallopian Tube Neoplasms+12 more

Estimated

~$10 – $750

Massachusetts General HospitalNCT04794322

Phase 1

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety a…

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms+3 more

Estimated

~$10 – $8,750

Bio-Path Holdings, Inc.NCT04196257